Petvivo Holdings, INC

PetVivo Holdings, Inc. announced the appointment of Jaime K. Pickett, DVM, MBA, to its Board of Directors, effective September 22, 2026, filling a vacancy.

PetVivo Holdings, Inc. announced the appointment of Michael K. Handley to its Board of Directors, effective September 22, 2026, to fill a vacancy.

PetVivo Holdings, Inc. has filed a Form 8-K to disclose an investor presentation that may be used in upcoming conferences and forums.

PetVivo Holdings, Inc. announced the resignation of its independent auditor, Stephano Slack LLC, effective July 2, 2026, and the engagement of GuzmanGray, A Professional Accountancy Corporation as its new auditor.

PetVivo Holdings has entered into a definitive merger agreement to acquire PiezoBioMembrane, Inc. to expand its functional biomaterials and regenerative medicine platform.

PetVivo Holdings has received the final $600,000 installment of a $1,000,000 private equity offering, with an option for further capital.

PetVivo Holdings reported increased revenues for Q1 2027, but faces substantial doubt regarding its ability to continue as a going concern due to ongoing net losses and accumulated deficit.

PetVivo Holdings, Inc. reported increased revenue driven by new product sales but saw a wider net loss for Q2 2026, alongside significant debt conversions and ongoing going concern doubts.

PetVivo Holdings, Inc. announced a significant increase in revenue for the quarter ended June 30, 2025, driven by new product sales, while also securing $5 million in Series B preferred stock funding to bolster liquidity.

PetVivo Holdings reports a slight decrease in revenue for the third quarter of fiscal year 2025, while implementing cost-cutting measures to reduce operating expenses.

PetVivo Holdings, Inc. reported its financial results for the quarter ended September 30, 2024, showing a decrease in net losses compared to the same period last year, while continuing to focus on commercializing its lead product, Spryng.

PetVivo Holdings reported a net loss of $2.047 million for the quarter ended June 30, 2024, while navigating a delisting from the Nasdaq stock market.

PetVivo Holdings, Inc. filed its annual report for the fiscal year ended March 31, 2026, detailing revenues of $1.14 million and a net loss of $10.47 million, while highlighting progress in product development and distribution partnerships.

PetVivo Holdings, Inc. announced a significant reduction in its net loss for fiscal year 2025, driven by increased product sales and decreased operating expenses, while securing a substantial Series B Preferred Stock offering to bolster future operations despite ongoing going concern doubts and internal control deficiencies.

PetVivo Holdings, Inc. has filed an amendment to its annual report to update business descriptions, risk factors, financial analysis, and executive compensation details.

PetVivo Holdings, Inc. outlines its share structure, warrant details, and corporate governance policies in its annual 10-K filing.

Robert James Rudelius, a Director of PetVivo Holdings, Inc., reported multiple transactions in common stock on September 18, 2026.

A.L. Sarroff Fund, LLC reported changes in beneficial ownership of PetVivo Holdings, Inc. common stock on August 27, 2026.

Garry N Lowenthal, Chief Financial Officer of PetVivo Holdings, Inc., reported multiple transactions in common stock on September 8, 2026.

John Lai, Chief Executive Officer and a Director of PetVivo Holdings, Inc., reported multiple transactions in common stock on September 9, 2026.

Garry N Lowenthal, Chief Financial Officer of PetVivo Holdings, Inc., reported multiple transactions in common stock on September 8, 2026.

John Lai, Chief Executive Officer and a Director of PetVivo Holdings, Inc., reported multiple transactions in common stock on September 9, 2026.

PetVivo Holdings, Inc. announces stockholder approval of director elections and auditor ratification through written consent, bypassing a formal meeting.

A Schedule 13D filing reveals the A.L. Sarroff Fund, LLC, Alan Sarroff, and Eileen Sarroff collectively hold 38.2% of PetVivo Holdings' common stock, with recent open market purchases.

A.L. Sarroff Fund, LLC and its principals increased their beneficial ownership in PetVivo Holdings, Inc. to 39.6% through a new private placement and warrant agreement.

A.L. Sarroff Fund, LLC and its principals, Alan and Eileen Sarroff, have disclosed a significant beneficial ownership of 36.1% in PetVivo Holdings, Inc. common stock.

Alexander Nazarenko has reported beneficial ownership of 8,044,085 shares, representing 18.73% of the outstanding common and preferred stock of PetVivo Holdings, Inc., as of July 24, 2026.

Stanley Cruden has reported a beneficial ownership of 9.37% in PetVivo Holdings, Inc. common stock as of December 31, 2025.

A.L. Sarroff Fund, LLC has increased its beneficial ownership in PetVivo Holdings, Inc. to 31.7% of common stock, as disclosed in its latest Schedule 13G filing.

Stanley C. Cruden has reported beneficial ownership of 9.8% of PetVivo Holdings, Inc.'s common stock as of March 31, 2025.

Stanley C. Cruden has filed an amended Schedule 13G, reporting beneficial ownership of 10.0% of PetVivo Holdings, Inc.'s Common Stock.

A.L. Sarroff Fund, LLC has disclosed an increased beneficial ownership of 29.7% in PetVivo Holdings, Inc., holding 6,821,091 common shares as a passive investor.